# Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

> **NCT05350774** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 45 (estimated)

## Conditions studied

- Systemic Inflammation
- Neuroinflammation
- Microvascular Thrombosis

## Interventions

- **DRUG:** IV normal saline
- **DRUG:** IV immunoglobulin

## Key facts

- **NCT ID:** NCT05350774
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-07-10
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05350774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05350774, "Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05350774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*